Summary
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
Register to download
PRA Successfully Rescues Phase II Hematology Study
You may also be interested in:
Blog
Discovering the People Behind the Science: Dr. Aimee Payne
Read Story
Blog
World Rare Disease Day 2018: Join the Movement!
Read Story
Newsletter
RARE DISEASES NEWSLETTER Volume 10, July 2018
This quarterly publication will keep you up to date on PRA’s Rare Disease Team focus, achievements, and new initiatives.
View Resource
View all related content and resources for Rare Diseases
Explore Insights